

Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase

Christopher Swale, Valeria Bellini, Matthew Bowler, Nardella Flore, Marie-Pierre Brenier-Pinchart, Dominique Cannella, Lucid Belmudes, Caroline Mas, Yohann Couté, Fabrice Laurent, et al.

▶ To cite this version:

Christopher Swale, Valeria Bellini, Matthew Bowler, Nardella Flore, Marie-Pierre Brenier-Pinchart, et al.. Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase. Science Translational Medicine, 2022, 14 (656), 17 p. 10.1126/sci-translmed.abn3231. hal-03752215

HAL Id: hal-03752215 https://hal.inrae.fr/hal-03752215v1

Submitted on 5 Sep 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

1	
2	Altiratinib blocks Toxoplasma gondii and Plasmodium
3	falciparum development by selectively targeting
4	a spliceosome kinase
5	
6	Christopher Swale ^{1†*} , Valeria Bellini ^{1†} , Matthew W. Bowler ² , Nardella Flore ³ , Marie-Pierre
7	Brenier-Pinchart ¹ , Dominique Cannella ¹ , Lucid Belmudes ⁴ , Caroline Mas ⁵ , Yohann Couté ⁴ ,
8	Fabrice Laurent ⁶ , Artur Scherf ³ , Alexandre Bougdour ^{1*} and Mohamed-Ali Hakimi ^{1*}
9	
10	¹ Institute for Advanced Biosciences (IAB), Team Host-pathogen interactions and immunity to
11	infection, INSERM U1209, CNRS UMR5309, University Grenoble Alpes, Grenoble, France
12	² European Molecular Biology Laboratory, Grenoble, 71 Avenue des Martyrs, CS 90181,
13	38042 Grenoble, France.
14	³ Institut Pasteur, Université de Paris, Unité de Biologie des Interactions Hôte-Parasite, CNRS
15	ERL 9195, INSERM U1201, F-75015 Paris, France.
16	⁴ Univ. Grenoble Alpes, INSERM, CEA, UMR BioSanté U1292, CNRS, CEA, FR2048
17	38000, Grenoble, France.
18	⁵ Integrated Structural Biology Grenoble (ISBG) CNRS, CEA, Université Grenoble Alpes,
19	EMBL, 71 avenue des Martyrs, F-38042, Grenoble, France.
20	⁶ INRAE, Université François Rabelais de Tours, Centre Val de Loire, UMR1282 ISP,
21	Laboratoire Apicomplexes et Immunité Mucosale, 37380 Nouzilly, France.
22	
23	[†] These authors contributed equally to this work.
24	
25	* Correspondence to:
26	mohamed-ali.hakimi@univ-grenoble-alpes.fr - ORCiD: 0000-0002-2547-8233
27	alexandre.bougdour@univ-grenoble-alpes.fr - ORCiD: 0000-0002-5895-0020
28	christopher.swale@univ-grenoble-alpes.fr - ORCiD: 0000-0002-9739-7774
29	
30	Spliceosome targeting by altiratinib leads to <i>Toxoplasma</i> and <i>Plasmodium</i> inhibition.
31	

- 32 Key words: Toxoplasma gondii, Plasmodium falciparum, drug repurposing, kinase, splicing
- 33

34 Abstract

35 The apicomplexa comprise a large phylum of single-celled, obligate intracellular protozoa that 36 include Toxoplasma gondii, Plasmodium and Cryptosporidium spp which infect humans and 37 animals and cause severe parasitic diseases. Available therapeutics against these diseases are 38 limited by suboptimal efficacy and frequent side effects, as well as the emergence and spread 39 of resistance. We use a drug repurposing strategy and identified altiratinib, a compound 40 originally developed to treat glioblastoma, as a promising drug candidate with broad spectrum 41 activity against apicomplexans. Altiratinib is parasiticidal and blocks the development of 42 intracellular zoites in the nanomolar range and with a high selectivity index when used against 43 T. gondii. We have identified TgPRP4K of T. gondii as the primary target of altiratinib using 44 genetic target deconvolution, which highlighted key residues within the kinase catalytic site 45 that conferred drug resistance when mutated. We have further elucidated the molecular basis of 46 the inhibitory mechanism and species selectivity of altiratinib for T_g PRP4K as well as for its P. falciparum counterpart, PfCLK3. Our data identified structural features critical for binding 47 48 of the other PfCLK3 inhibitor, TCMDC-135051. Consistent with the splicing control activity 49 of this kinase family, we have shown that altiratinib can causes global disruption of splicing, 50 primarily through intron retention in both T. gondii and P. falciparum. Thus, our data establish 51 parasitic PRP4K/CLK3 as a potential pan-apicomplexan target whose repertoire of inhibitors can be expanded by the addition of altiratinib. 52

53

54 Introduction

55 Infectious diseases caused by apicomplexan parasites remain one of the leading causes of 56 morbidity and mortality around the world, with even more devastating consequences in low-57 income countries, underscoring the need for effective medicines. Plasmodium falciparum 58 causes malaria in over 240 million people worldwide and is responsible for more than 627 000 59 deaths in 2020 (1). Similarly, Toxoplasma gondii, the causative agent of toxoplasmosis, causes 60 widespread zoonotic infection, with nearly one-third of the world's population being 61 seropositive for this parasite. In healthy adults, the acute infection resolves rapidly, leaving a 62 chronic, subclinical infection in some individuals. In the absence of sustained immunity, 63 reactivation of latent forms of T. gondii leads to severe, life-threatening disease, as has been 64 observed in AIDS, organ transplant and chemotherapy patients, with a high mortality rate in

65 the absence of treatment (2). More severe cases may also occur following congenital 66 transmission of the parasite to an unborn child. In addition, *Toxoplasma gondii*, together with 67 other coccidian parasites, e.g. *Eimeria* spp. And *Neospora caninum*, are of veterinary 68 importance as they cause significant economic losses in livestock populations.

69

70 For many of these apicomplexa-mediated diseases, current treatments are suboptimal, and for 71 some there are few, if any, alternatives. The current standard treatment of toxoplasmosis is 72 based on a pyrimethamine-sulfadiazine combination but is hampered by severe side effects, 73 especially in immunocompromised individuals (3). For malaria, artemisinin-based combination 74 therapies (ACT) are currently used as first-line treatments in endemic countries worldwide, but 75 the emergence and spread of resistance not only to artemisinin but also to other drug 76 combinations is a growing threat (1). The ever-present threats of drug resistance have led to the 77 search for other therapeutic alternatives. Older drugs have recently made a comeback by being 78 repurposed for new diseases to accelerate drug development (4, 5). After phenotypic screening 79 for drug repurposing, new indications for existing drugs can be quickly identified and clinical 80 trials can be rapidly conducted. Identifying the target and understanding the mechanism of 81 action are critical bottlenecks in drug development, as these two phases provide the essential 82 chemical basis for targeted inhibition and pave the way for chemical derivatization of the 83 original drug candidate. Recent advances in genomics and target deconvolution strategies have 84 addressed these problems and have ushered in a plethora of putative targets awaiting 85 clarification.

86

87 Here, we report the identification of altiratinib from a chemical library that includes FDA-88 approved or phase I/ II clinical trial candidate drugs. Altiratinib exhibited potent, nanomolar, 89 broad-spectrum anti-apicomplexan activity with a high selectivity index and had previously 90 been in phase 1 clinical development for the treatment of invasive solid tumors, including 91 glioblastoma (6, 7). Using a genetic target deconvolution strategy, we identified T. gondii 92 TgPRP4K, the closest relative of the human splicing factor kinase PRP4 kinase 93 (PRP4K/PRPF4B) and Plasmodium falciparum PfCLK3 (8, 9), as the primary target of 94 altiratinib. In addition, we used an integrated structural biology approach to further elucidate 95 the molecular basis of the mechanism of inhibition of altiratinib and characterized the 96 remarkable selectivity of this drug for parasitic PRP4K/CLK3 enzymes. This kinase family 97 plays a critical role in cell cycle progression by regulating pre-mRNA splicing in all eukaryotic 98 lineages (10-13). Accordingly, altiratinib caused global disruption of splicing with exon 99 skipping, intron retention, and premature transcription termination in both *T. gondii* and *P. falciparum*, but not in *Cryptosporidium parvum*, in which the kinase has significantly divergent variations that may result in resistance to altiratinib. Our findings support this family of parasitic kinases as a promising apicomplexan target and highlight the structural determinants that explain the remarkable selectivity of altiratinib.

104

105 **Results**

A drug repurposing screen identifies altiratinib as a potent and selective apicomplexan inhibitor of parasite growth

108 To identify new drug candidates against toxoplasmosis and potential targets, we screened a 109 small library of 514 approved drugs or drugs undergoing clinical trials for their ability to inhibit 110 T. gondii tachyzoite growth. All compounds are structurally diverse, cell permeable, medically 111 active, and commercially available (Table S1). Screening was performed in duplicate at 5 µM 112 while pyrimethamine was used as a reference drug and blocked the growth of type I (RH) 113 parasites as expected. The compounds that showed reproducible inhibition of parasite growth 114 of >70% were selected for further testing (Fig. S1A; Table S1). Of the 514 compounds in the 115 collection, 75 primary hits were found to inhibit parasite growth without detectable cytotoxicity 116 to the host cell (Fig. 1A), preferentially targeting the cell cycle and tyrosine kinase/adaptor 117 signaling pathways (Fig. S1B; Table S1). A second screen at 1 µM of the 84 compounds 118 identified 14 molecules with EC_{50} in the nM range (Fig. 1B; Fig. S2). The most potent growth 119 inhibitor we identified was altiratinib (DCC-2701, DP-5164, Fig. 1C) with an EC₅₀ of 28 nM 120 against tachyzoites, which is 11-fold lower than pyrimethamine (300 nM), the standard 121 treatment for toxoplasmosis (Fig. 1D). Altiratinib-treated parasites were smaller than the 122 control group and no longer divided, as no daughter cells were detectable (Fig. 1E). Plaque 123 assays showed sustained inhibition of parasite growth, as plaques could no longer be detected 124 in the presence of altiratinib, suggesting a defect in one or more steps of the lytic cycle (Fig. 125 S3). Interestingly, we did not observe regrowth within 6 to 10 days after discontinuation of 126 altiratinib, suggesting that the drug has a cidal effect in contrast to pyrimethamine (Fig. S3). 127 Altiratinib also showed low host cytotoxicity compared with THZ1 used as a cytotoxic control 128 (Fig. S1D), resulting in a high selectivity index (SI) with a value of 400 for human primary 129 fibroblasts (Fig. 1F). Altiratinib was also effective in inhibiting the growth of coccidial parasites 130 of veterinary importance such as *Eimeria tenella* (Fig. 1G) and *Neospora caninum* (Fig. 1H),

as well as *P. falciparum*, although its efficacy is lower compared with the antimalarial drug
dihydroartemisinin (DHA) (Fig. 1i).

133

Altiratinib target deconvolution by EMS-based forward genetic screen identifies *TgPRP4K* as a resistance gene

136 Altiratinib was originally identified to inhibit tumor growth and invasion in a bevacizumab-137 resistant glioblastoma mouse model and was in phase 1 clinical development for the treatment 138 of invasive solid tumors. The drug was predicted to be a pan-tyrosine kinase inhibitor of MET, 139 TIE2, VEGFR2, and TRK (6, 7), but none of these kinases are conserved in apicomplexa. 140 Therefore, to explore the mechanism of action of altiratinib in T. gondii, we performed a 141 forward genetic screen combining chemical mutagenesis and RNA sequencing, as previously 142 described (14) (Fig. S1E). Altiratinib-resistant parasites were generated in 6 independent 143 chemical mutagenesis experiments using 2.5 mM ethyl methanesulfonate (EMS) followed by 144 selection in the presence of 300 nM altiratinib, i.e. 10-fold the EC₅₀ value, for approximately 4 145 weeks. The resistant parasite lines were then cloned by limited dilution, and a single clone from 146 each mutagenesis experiment (designated A to F) was analyzed by whole-genome RNA 147 sequencing (RNA-Seq). To map the EMS-induced mutations conferring resistance to 148 altiratinib, Illumina sequencing reads were aligned to the T. gondii GT1 reference genome. 149 Using the parental strain as a reference, single nucleotide variants (SNVs) were identified in 150 the assembled sequences of the resistant mutants (see *Materials and Methods*). By focusing on 151 mutations in coding sequences, a single gene, TGGT1 313180, contained SNVs that resulted 152 in amino acid changes (F647S, L686F, L715F) not present in the parental strain in five of the 153 six drug-resistant lines (Fig. 2, A and B; Table S2).

154

155 TGGT1_313180 encodes a 928 amino acid (aa) protein that has a predicted kinase domain in 156 its C-terminus, hereafter referred to as TgPRP4K (Fig. 2B). TgPRP4K is phylogenetically 157 related to the cyclin-dependent-like kinase family (CLK) (15, 16) and its closest homolog in 158 humans is the splicing factor kinase PRP4 kinase (PRP4K or PRPF4B) and in *P. falciparum* is 159 PfCLK3 (PF3D7_1114700), a kinase that has been identified as a multistage cross-species 160 antimalarial drug target (Fig. S4A) (8, 9, 17). Immunofluorescence analysis of intracellular 161 parasites showed that TgPRP4K is localized to nuclear speckle-like structures (Fig. 2C). 162 $T_{g}PRP4K$ is essential for the lytic cycle of tachyzoites, as its genetic disruption results in a 163 fitness score of -4.69 (18), and conditional knockdown of the kinase using the auxin-inducible

degron system (AID) dramatically impaired parasite growth (Fig. 2D) in agreement with arecent study (*19*).

166

167 Surprisingly, the altiratinib-resistant parasite line from mutagenesis F has a wild-type (WT) 168 allele of TgPRP4K and a mutation E1325K in TgPRP8, a protein located in the catalytic core 169 of the spliceosome that has been shown to interact with PRP4K in Schizosaccharomyces pombe 170 to facilitate spliceosome activation (20, 21). This reinforces the possibility that the PRP4K-171 PRP8 complex is at the basis for the anti-Toxoplasma activity of altiratinib. The specific 172 association between TgPRP4K and TgPRP8 was then confirmed by FLAG affinity 173 immunoprecipitation and mass spectrometry (MS)-based proteomic analyzes using knock-in 174 parasite lines expressing a tagged version of each protein (Table S3; Fig. S4, B and C). Other 175 partners have been identified as pre-mRNA splicing proteins constitutive of the core 176 spliceosome, such as U2 snRNP proteins and U5 snRNP proteins, including the RNA helicase 177 Brr2 and Snu114, which forms a pocket enclosing the catalytic RNA network of activated 178 spliceosomes (Fig. S5) (21, 22). Known pre-mRNA splicing factors were also purified along 179 with PRP4K and PRP8 (Table S3; Fig. S4, B and C; Fig. S5). TgPRP4K was found in a high 180 molecular-weight complex (~500 kDa; fractions 24–26) that withstood stringent salt conditions 181 and partially co-eluted with the TgPRP8-containing spliceosome, which migrates by size 182 exclusion chromatography with an apparent molecular weight of ~900 kDa (fractions 18-20) 183 (Fig. S4, B and C).

184

185 Single mutations within *Tg*PRP4K confer resistance to altiratinib

186 To confirm that the mutations found in TgPRP4K and TgPRP8 were sufficient to confer 187 resistance to altiratinib, we used the CRISPR/Cas9 system in conjunction with homology-188 directed repair, to reconstruct each of the etiological mutations into the susceptible parental T. 189 gondii strain (14). Parasites were cotransfected with a vector expressing the Cas9 endonuclease 190 and a synthetic guide RNA (sgRNA) targeting either TgPRP4K or TgPRP8, and the 191 corresponding homologous single-stranded donor oligonucleotides (ssODN) as repair 192 templates (Fig. S6A). After altiratinib selection, the resistant parasites were cloned, and DNA 193 sequencing confirmed that the mutations were properly introduced at the *TgPRP4K* locus (Fig. 194 S6B). Note that despite numerous attempts, allelic substitution for TgPRP8 could not be 195 achieved, suggesting that the TgPRP8 (E1325K) mutation alone does not confer resistance to 196 altiratinib and was not investigated further. Compared with WT parasites, mutant strains edited

197 for TgPRP4K (mutations F647S, L686F, and L715F) significantly decreased sensitivity to 198 altiratinib by 50- to 180-fold (Fig. 2, E to G; Fig. S6C), suggesting that resistance to altiratinib 199 correlates with TgPRP4K activity. In addition, the CRISPR/Cas9-edited lines had altiratinib 200 resistance levels at least as high as the EMS-mutagenized clones (Fig. S7; Table S2). This 201 suggests that the reconstructed TgPRP4K mutations fully recapitulate the resistance phenotype 202 originally observed in the mutagenized lines, and that it is unlikely that other secondary 203 mutations are involved in the resistance mechanism. It is worth noting that the CRISPR/Cas9-204 edited parasite with the F647S mutation exhibited a higher level of resistance to altiratinib than 205 its mutant counterpart, most likely due to overall growth failure of the latter (Fig. S7).

206

207 Structural studies uncover the mechanism of action of altiratinib on *Tg*PRP4K

208 To unravel the molecular mechanism of action of altiratinib inhibition, we expressed the 209 predicted kinase domain of TgPRP4K in the WT and L715F variant versions by removing the 210 intrinsically disordered region at the N-terminus (Fig. S8A). Both recombinant proteins were 211 produced in satisfactory yields, with the notable difference being a higher size homogeneity of 212 the L715F mutant (Fig. S8B) when analyzed by size exclusion chromatography coupled to laser 213 light scattering (SEC-MALLS). The same sample did not display a double band that can be 214 seen in the WT (Fig. S8C) and was also observed in Flag-purified human WT PRPF4B as a 215 result of posttranslational modifications (23). The L715F mutation is peculiar because it 216 centered on the DFG (Asp-Phe-Gly) motif, which is a DLG (Asp-Leu-Gly) in apicomplexan 217 parasites. DFG (or DLG in a subset of kinases, such as RIPK1) is a highly conserved peptidic 218 motif found in most human kinases and is critical for allosteric placement of the activation loop. 219 Using a thermal stability assay and a thermophoresis titration assay, we could show a direct 220 stabilizing effect (delta Tm of 11°C) and binding (apparent Kd of 64 nM) of altiratinib with the 221 WT TgPRP4K kinase domain (Fig. 3, A and B). Counterintuitively though, the L715F mutation 222 does not decrease altiratinib binding, but instead increases binding affinity (Fig. 3, A and B). 223 This not only increases the apparent Kd value (26 nM), but also increases the stabilizing effect 224 of the compound *in vitro* compared to WT (with a Δ Tm of 15 °C). This surprising observation 225 highlights an unusual resistance mechanism that should somehow compensate for the inhibitory 226 mechanism, regardless of the binding affinity of the compound. Using this point mutant, we 227 successfully co-crystallized *Tg*PRP4K in complex with altiratinib and obtained high-resolution 228 diffraction to 2.3Å (pdb id: 7Q4A, Table S4). A molecular replacement solution was found with 229 the human homolog of PRPF4B kinase domain (pdb id: 6CNH), which shares 47% sequence

230 identity with TgPRP4K. The structure solution showed TgPRP4K crystallizing as a dimer with 231 the catalysis cavities facing each other (Fig. S9A). The monomer B exhibited more complete 232 density within the flexible regions, so all further structural representations are based on this 233 monomer. The activation loop was fully assembled in our model and occupies a DFG "out" 234 conformation while the tyrosine 729 is phosphorylated in this structure (Fig. 3C, Fig. S9B and 235 C). Interestingly, this phospho-tyrosine is central to the ability of *Tg*PRP4K to crystallize under 236 these conditions, as it forms numerous crystal contacts with other symmetry-related molecules 237 (Fig. S9B).

238

239 The activation loop displays an alpha helix (Ile 726 to Tyr 735) that appears to be unique to T. 240 gondii PRP4K when compared to the human ortholog, which was only ever crystallized in DFG 241 "in" conformations and is largely a random coil in this state (Fig. 3C, Fig. S9C). Compared to 242 the human ortholog in its global structure, TgPRP4K is structurally conserved, with minor 243 structural differences in the C-terminal portion (aa 840 to 854) of the kinase domain (Fig. S9C). 244 The structure also reveals a C-terminal antiparallel short beta strand that, to our knowledge, is 245 unique to the PRP4K kinase lineage (Fig. 3C) and is also structurally conserved in the human 246 ortholog (Fig. S9C), although sequence conservation for this region is very low.

247

248 Electron density for altiratinib was clearly visible in our crystal structure and interacts in the 249 ATP-binding pocket located at the interface between the N- and C-lobes (Fig. 3C), with the 250 DFG motif and the G-rich loop closing off this cavity. It is noteworthy that both monomers 251 display strong electron density for altiratinib, allowing us to confidently assign the entire 252 molecule (Fig. S10A). More detailed analysis revealed that the interaction of the compound 253 within the cavity relies on numerous hydrophobic interactions (Fig. 3D; Fig. S10, B and C), 254 which can be divided into three distinct zones. The first zone, consisting of a cyclopropane-255 carbonylamino group connecting a pyridine ring, interacts mainly with side chains W649, L650, 256 W651, L702 and A595 (Fig. 3D, Fig. S10C). Hydrogen bonds also form with the carbonyl and 257 amide groups of the leucine 650, and most of these residues form the ATP-binding hinge region, 258 leading to the deeper allosteric pocket. The second zone of altiratinib is central and consists 259 mainly of a difluorophenyl ring stacked between the two phenylalanines 647 and 715 (the DFG 260 central residue, which is a leucine in wild type TgPRP4K) (Fig. 3D), with one of the fluorine 261 groups interacting with the sulfur group of C713 (Fig. S10C). These interactions ensure that the 262 activation loop remains in this « out » position. Finally, the last part of altiratinib which

263 encompasses a cyclopropane-1,1-dicarboxamide leading to a fluorophenyl ring, is buried deep 264 in the allosteric cavity and interacts with multiple residues within the C-lobe, notably the 265 glutamic acid 612 and leucine 616 and 619, which line up on the C-alpha-helix (Fig. 3D, Fig. 266 S10C). Other interactions are mediated by I630 and L686, as well as the H693, which belongs 267 to the canonical HxD triad that is a H/A/D in PRP4K proteins. Only one residue within the N-268 lobe, the catalytic lysine K597, forms a hydrogen bond with the central carboxy group. Using 269 this structure, we can now rationalize the consequences of the resistance mutations triggered by our EMS screen. All of the point mutations we obtained involve residues that interact directly 270 271 with altiratinib, whereas the direct mechanisms of resistance are likely quite different (Fig. 3E). 272 The L686F mutation logically introduces a steric hindrance for the fluorophenyl ring by 273 significantly increasing the size of the side-chain. The other two resistance-conferring 274 mutations, F647S and L715F, involve residues in direct interaction and at opposite sides of the 275 central difluorophenyl ring. F647S probably strongly decreases hydrophobic stacking, while 276 we have evidence that the mutation L715F does not cause steric hindrance but, on the contrary, 277 probably increases hydrophobic stacking of the difluorophenyl ring. As such, most of the 278 mutated residues are highly conserved elements found in both HsPRPF4B and TgPRP4K (the 279 L715F is a significant divergence but does not negatively affect compound binding) and are 280 unlikely to be involved in interspecies binding selectivity. Altiratinib is not recognized as an 281 inhibitor of PRPF4B in human cells, as it was originally designed to inhibit the kinases MET, 282 TIE2 (TEK), and VEGFR2 (KDR) (6, 7). Of the residues involved in binding to altiratinib, 283 most are strictly conserved among PRPF4B orthologs (Fig. 3E), but the hinge region has 284 residues (W649 and W651) that diverge considerably from the human ortholog, being replaced 285 by a proline and serine, respectively.

286

287 Hinge region residue 649 controls species specificity of altiratinib towards TgPRP4K

288 The superposition of the human and T. gondii PRPF4B/PRP4K structures makes it clear that 289 the hinge region has a consistent backbone structure despite significant differences in side chain 290 composition (Fig. 4A). More importantly, this overlay shows that the change from W649 to 291 P769 would affect the main hydrophobic component that stacks the cyclopropane-292 carbonylamino and pyridin groups of altiratinib. A similar, albeit lesser, role can also be 293 attributed to W651, whose equivalent residue in humans is S771 and likely reduces the 294 hydrophobic caging potential toward altiratinib. To test the significance of residue W649, we 295 used the same CRISPR-Cas9 complementation approach for SNV validation to generate a 296 "humanized" mutant W649/P that requires a codon change from TGG to CCG (Fig. 4B). The

297 probability of such a change occurring in EMS mutagenesis is low because it requires a 298 simultaneous alteration of two nucleotides. This substitution is not prevalent in EMS 299 mutagenesis, which preferentially alkylates G residues (24). Interestingly, this artificial 300 humanization produced parasites that were resistant to altiratinib (Fig. 4, C to E) and had an 301 EC50 of 3.5 μ M, which is comparable to the mutations using the EMS approach. Using TgPRP4K WT, L715F and W649P expressed in insect cells, we were able to probe the *in vitro* 302 303 consequences of these two different mutations on the ability of the protein to interact with 304 altiratinib. Using an indirect thermal shift assay and a thermophoresis approach (Fig. 4, F to H), 305 we demonstrated that the hydrophobic stacking of W649 is essential for altiratinib binding, as 306 almost no stabilization is observed in the presence of altiratinib (delta Tm of 3 °C), compared 307 to WT PRPF4B (Delta Tm of 11°C, Fig. 3A), while the apparent Kd measured in 308 thermophoresis transitions from 64 nM to not measurable (Fig. 3B and Fig. 4G).

309

Finally, we tested these sets of recombinant wild-type and mutant TgPRP4K proteins to assess the inhibitory effect of altiratinib on *in vitro* endpoint kinase activity using a reporter assay for ATP content and PRP31 peptide as substrate. In this context, WT TgPRP4K shows measurable kinase activity and exhibits the highest sensitivity to altiratinib with an apparent IC50 of 13 nM (Fig. 4i). The L715F mutant binds with higher affinity to altiratinib but is significantly less sensitive with an apparent IC50 of 62 nM. The W649P mutation brings the greatest tolerance to altiratinib, as the apparent IC50 now ranges at more than 300 nM (Fig. 4i).

317

318 Chemically induced inactivation of *Tg*PRP4K activity disturbs pre-mRNA splicing in *T*. 319 *gondii*

320 Since it has been proposed that the human kinase PRPF4B and PfCLK3 regulate RNA splicing 321 (8, 10), we examined transcriptional changes in the parental parasite RH and in the drug-322 resistant strains L715F and W649P in response to exposure to altiratinib using nanopore long-323 read direct RNA sequencing (DRS), a technology well suited for determining the full repertoire 324 of mRNA species, including alternative splicing isoforms and divergent patterns, if present. 325 The most obvious effect was that a substantial number of genes (n=2400) showed altered 326 mRNA expression, of which 784 were induced and 1616 repressed when the parent strain was 327 treated with altiratinib, whereas no significant changes were observed in the two mutant strains 328 exposed to the drug (Fig. 5A). This confirms that altiratinib disrupts mRNA transcription, 329 which was expected, but also that the drug specifically targets TgPRP4K, as both mutations not 330 only confer resistance (Fig. 2, D to F) but also restore gene expression to the untreated state

331 (Fig. 5A). Having identified isoforms with high confidence using the Nanopore data, we used 332 FLAIR (Full-Length Alternative Isoform Analysis of RNA) (25) as a framework for analyzing 333 differential isoform usage in wild-type and mutant strains left untreated or exposed to altiratinib. 334 The most important transcriptional phenotype was the change in pre-mRNA splicing dynamics 335 associated with inhibition of TgPRP4K exclusively in WT parasites (Fig. 5B). At many loci, 336 chemical inactivation of TgPRP4K was accompanied by complete retention of the second intron 337 (e.g., TGME49 214940; Fig. 5, B and D) or intron retention and exon skipping at the same loci 338 (e.g., TGME49 211420 and TGME49 247350; Fig. 5C; Fig. S11A). When an intron is spliced, 339 it rapidly promotes splicing of subsequent introns, whereas when splicing is hindered, 340 subsequent introns tend to be retained, leading to the concept of 'all or none' splicing (26, 27). 341 Consistent with this concept, we regularly observed a global collapse of splicing along the entire 342 transcript (e.g., TGME49 208450; Fig. S11B) after drug treatment.

343

344 Since splicing is predominantly co-transcriptional, we also observed that intron retention leads to premature transcriptional termination (e.g., TGME49 278940; Fig. S11C). At the 345 346 transcriptome level, intron retention is the predominant aberrant splicing event found in 347 altiratinib-treated WT tachyzoites in contrast to the host cells they infect, underscoring the high 348 degree of selectivity of altiratinib (Fig. 5E). Upon closer inspection, we found that intron 349 retention leads to premature termination of translation due to frameshifts, which may ultimately 350 lead to altered function of the protein-coding gene. In addition, aberrant isoforms are degraded, 351 as indicated by the lower read rates at some *loci*, likely through nonsense-mediated decay 352 (NMD), a quality control mechanism that eliminates transcripts with a premature termination 353 codon. In this way, treatment with altiratinib leads to the production of defective proteins that 354 ultimately affect parasite survival.

355

Altiratinib also causes mis-splicing in *P. falciparum* but not in *C. parvum*, which has a divergent PRP4K ortholog

Because altiratinib was active against a wide range of apicomplexans (Fig. 1) and the PRPK4/CLK3 family was well conserved within the phylum, we wondered whether the drug might inhibit splicing in other parasites of the phylum. We first examined transcriptional changes of red blood cells infected with *P. falciparum* after treatment with altiratinib using Nanopore DRS. All types of splicing defects that we had observed in *T. gondii* were also present in *P. falciparum*, such as exon skipping, intron retention, and premature transcription

364 termination (Fig. 6A; Fig. S12, A to C), with a general trend toward global splicing collapse 365 along the entire transcript, with premature mRNAs being highly susceptible to NMD 366 degradation (Fig. S12, A to C), As with T. gondii, markedly increased intron retention is a 367 conserved phenomenon in P. falciparum exposed to altiratinib (Fig. 6B). These results 368 underscore the potential targeting by altiratinib of *Pf*CLK3 (*PF3D7_1114700*), a kinase that is 369 essential for P. falciparum survival in red blood cells and plays a critical role in regulating RNA 370 splicing of the malaria parasite (8, 9). We then took the opportunity to test the drug on 371 Cryptosporidium parvum, a parasite of the phylum that differs from others in having a 372 significantly divergent ortholog of PRP4K/CLK3 (cgd8_5180, Fig. S4A), specifically the 373 resistance-conferring DFG motif instead of the DLG motif found in T. gondii and P. falciparum, 374 but also several significant mutations at other altiratinib-interacting residues (L719 to F, W651 375 to H, and C713 to S) that may strongly affect the binding selectivity of altiratinib (Fig. S12, D 376 and E). As expected, we observed no defects in mRNA splicing in C. parvum exposed to 377 altiratinib (Fig. 6, C and D; Fig. S12D), again confirming the selectivity of the drug for 378 PRP4K/CLK3 with a DLG motif and ruling out off-target activities (Fig. S12E).

379

380 Assessing the ins and outs of CLK3/PRP4K inhibition by altiratinib or TCMDC-135051

381 To further confirm *P. falciparum Pf*CLK3/PRP4K as a target of altiratinib, we expressed the 382 WT PfPRP4K kinase domain to probe this biochemical interaction (Fig. S13A). Using the 383 previously described thermal shift assay, we found that altiratinib indeed stabilizes PfCLK3, 384 albeit with a weaker potential, the delta Tm is of 4°C, compared to TgPRP4K, which has a delta 385 Tm of 11°C (Fig. 6E). Interestingly, however, when probing the TCMDC-135051 compound, 386 a recently discovered inhibitor of PfCLK3 (9), we observed a reversed trend with a stronger 387 stabilizing effect on PfCLK3 with a delta Tm of 10°C instead of 7°C for TgPRP4K (Fig. 6E). 388 These results highlight two important aspects. First, we confirm that TCMDC-135051 likely 389 binds the active site of *Pf*CLK3 as the energy requirements for such a stabilizing effect would 390 probably only occur within a buried cavity strongly interacting with the compound. Second, 391 this also highlights that there may still be some species selectivity between the two compounds. 392 As we were unable to crystallize *Pf*CLK3 in the bound or unbound state, we used alphafold2 393 (28) within collabfold (29) to create a model that we superposed to our crystallographic 394 structure and manually docked TCMDC-135051, taking advantage of the structural homology 395 to other hinge regions binders containing a 7-azaindole scaffold (Fig. S13B, as initially 396 proposed in 9). In this modeling (Fig. 6F), we observe that most of the PRP4K/CLK3 hinge

region is conserved between *P. falciparum* and *T. gondii*, in particular residues W649/W651 in *Tg*PRP4K, which are also fully conserved in *Pf*CLK3 (W446/W448) and likely also have an
important impact on the selectivity of TCMDC-135051, particularly through hydrophobic
stacking. However, the conformation of the activation loop is not consistent with the binding

- 401 of TCMDC-135051 in the TgPRP4K structure (Fig. 6F), indicating potential differences in the
- 402 activation loop conformation that may differ between TCMDC-135051 and altiratinib.
- 403

404 **Discussion**

405 Our studies define altiratinib as a promising apicomplexan drug candidate effective against the 406 human pathogens T. gondii and, with lesser efficacy, P. falciparum, as well as N. caninum and 407 E. tenella of veterinary interest. Using genetic, structural and transcriptional approaches, we 408 have shown that repurposing of altiratinib disrupts mRNA splicing in T. gondii and P. 409 falciparum by targeting the kinase core of PRP4K/CLK3. The induced splicing defects are so 410 extensive that they lead to irreversible inhibition in the nanomolar range of rapidly proliferating 411 apicomplexan zoites in cellular assays. Using a genetic target-deconvolution strategy, we have 412 highlighted key residues involved in binding to altiratinib. Unexpectedly, this has allowed us 413 to crystallize and resolve the first structure of a previously elusive apicomplexan kinase 414 PRP4K/CLK3. This co-crystal structure allows us to assign the electron density of altiratinib, 415 located at the interface between the N- and C-terminal lobes and occupying both the ATP-416 binding site and the allosteric pocket, a singular type of binding that holds PRP4K in a DFG-417 out conformation consistent with inhibition of the type II kinases. The structural data have 418 clarified many unanswered questions related to the species selectivity of altiratinib, as we now 419 know that its ability to discriminate the human ortholog and bind the parasitic PRP4K/CLK3 is 420 constrained by residues W649/W651 in the hinge region (Fig. 4A), which have diverged 421 significantly and are also likely critical for binding of the recently discovered PfCLK3 inhibitor 422 TCMDC-135051 (Fig. 6F) (8, 9). Another important divergence is the shift from DFG to DLG 423 that has occurred between mammals and some apicomplexans. DLG is indeed associated with 424 inactive or less active kinases such as ROR2 (30, 31), and the selective pressure that led to this 425 mutation is not yet clear, as DFG-mutated tachyzoites behave normally in cell cultures (Fig. 2, 426 D to F). DLF conversion to DFG results in resistance to altiratinib, both *in vivo* and *in vitro* 427 activity assays. This observation, although counterintuitive, is not unique, as other resistance-428 conferring mutations in Abl, RET, and EGFR have been shown to promote resistance by 429 increasing kinase activity without altering the binding properties of the drug (32-34). This likely 430 gain in activity is sufficient to resist altiratinib both *in vivo* and *in vitro*, although binding 431 affinities are increased. Our work highlights the utility of drug repurposing and provides 432 structural mechanistic insights into understanding how the PRP4K/CLK3 family is susceptible 433 to selective pharmacological inhibition by small drug-like molecules. This opens new 434 opportunities to chemically improve existing molecules to optimize pathogen killing via the 435 PRP4K/CLK3 pathway.

436

437 However, some open questions and study limitations remain. Although the evidence for a direct 438 interaction between altiratinib and PRP4K/CLK3 and drug-induced mis-splicing is 439 overwhelming, the possibility that TgPRP4K acts as a resistance gene cannot be ruled out. 440 Moreover, the true mechanism of spliceosome inhibition is still in question, as PRP4K not only 441 plays a role in pre-B spliceosome activation by phosphorylating other components of PRP, 442 notably PRP6 and PRP31 (10), but also structurally integrates the complex (21) and contacts 443 the RNase PRP8, which may be allosterically involved in its activity. Inhibition of activity or 444 conformational entrapment (or both) may therefore be the key to proper inhibition. 445 Furthermore, the *in vitro* inhibition assay had to be performed with protein concentrations 446 higher than the apparent IC₅₀ (107 nM) and display inherent differences in intrinsic activity 447 (between wild-type and mutated recombinant *Tg*PRP4K). Although the relative distribution of 448 the $IC50_{app}$ values confirms the trend toward resistance, IC_{50} values are influenced by 449 stoichiometric (tight) binding kinetics and may be overestimated in this context.

450

451 Our structural model is also built on a L715F mutated TgPRP4K which has provided us with a 452 stable crystal system. While the placement of altiratinib will not change, the activation loop 453 dynamics are probably different in the wild-type context. PfCLK3 has been identified as a 454 multistage cross-species malarial drug target and TCMDC-135051 a drug candidate with a high 455 curative and transmission-blocking potential (8, 9). Altiratinib and TCMDC-135051 have a 456 very different chemical space (Fig. S13B) and although they probably rely on comparable 457 elements within the hinge region to selectively bind apicomplexan PRP4K/CLK3, species 458 selectivity is still present, possibly due to differences in the dynamics of the activation loop 459 with which binding is compatible. Dual (SAR)-directed optimization will therefore open the 460 possibility of developing a pan-apicomplexan therapy based on the altiratinib/TCMDC-135051 461 combination.

462

463 Materials and Methods

464

465 Study Design

466 This study includes three sequential phases. An in vitro phenotypic screen using T. gondii 467 tachyzoites infecting single-layered cells to identify potent inhibitors within a small library of 468 repurposable drugs. The second phase was to determine the inhibitory properties of the lead 469 compound altiratinib and identify resistance-conferring genes by chemical mutagenesis of T. 470 *gondii*, mapping of point mutations, and complementation in a wild-type background. The third 471 phase was to confirm the mechanism of action of altiratinib on TgPRP4K by in vitro biophysical 472 methods, experimental structural biology, and functional transcriptomics in several 473 apicomplexan parasites cultured in vitro. Sample sizes were based on similar experiments in 474 the literature and are indicated in the figure legends. Whenever possible, replicate or triplicate 475 measurements were performed. Proteomic, transcriptomic or structural experimental data were 476 deposited in curated databases when available. This study was not blinded.

477

478 Toxoplasma gondii, Plasmodium falciparum and human cell culture. Human primary 479 fibroblasts (HFFs, ATCC® CCL-171TM) were cultured in Dulbecco's Modified Eagle Medium 480 (DMEM) (Invitrogen) supplemented with 10% heat inactivated Fetal Bovine Serum (FBS) 481 (Invitrogen), 10 mM (4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid) (HEPES) buffer 482 pH 7.2, 2 mM L-glutamine and 50 µg/ml of penicillin and streptomycin (Invitrogen). Cells were 483 incubated at 37°C in 5% CO2. The Toxoplasma strains used in this study and listed in Table S5 484 were maintained in vitro by serial passage on monolayers of HFFs. The cultures were free of 485 mycoplasma, as determined by qualitative PCR. P. falciparum parasites were cultured using 486 standard culture conditions (35). The drug sensitive laboratory strain 3D7 was used in this 487 study.

488

489 *Toxoplasma gondii* genome editing. Targeted genome modifications were performed using 490 the *T. gondii* adapted CRISPR/Cas9 system as previously described (*36*). Recombinant 491 parasites harboring allelic replacement for PRP4K^{F647S}, PRP4K^{L686F}, PRP4K^{L715F}, and 492 PRP4K^{W649P} were generated by electroporation of the *T. gondii* RH NLuc strain with 493 pTOXO_Cas9CRISPR vectors targeting the *PRP4K* coding sequence (sgPRP4K^{F647S}, 494 sgPRP4K^{L686F}, sgPRP4K^{L715F}) and their respective donor single-stranded oligo DNA 495 nucleotides (ssODNs) carrying respective nucleotide substitutions (PRP4K^{F647S}_donor, PRP4K^{L686F}_donor, PRP4K^{L715F}_donor; Table S5) for homology-directed repair. Recombinant
parasites were selected with 300nM altiratinib prior to subcloning by limited dilution, and
allelic replacement was verified by sequencing of *T. gondii TgPRP4K* genomic DNA.

499

500 Toxoplasma gondii random mutagenesis. Parasites (RH strain) were chemically mutagenized 501 as previously described (14), with the following modifications. Briefly, $\sim 10^7$ tachyzoites 502 growing intracellularly in HFF cells in a T25 flask were incubated for 4 h at 37°C in 0.1% FBS 503 DMEM growth medium containing either 2.5 mM ethyl methanesulphonate (EMS) at final 504 concentration or the appropriate vehicle controls. After exposure to the mutagen, parasites were 505 washed three times with PBS, and the mutagenized population was allowed to recover in a fresh 506 T25 flask containing an HFF monolayer in the absence of drug for 3-5 days. The released 507 tachyzoites were then inoculated into fresh cell monolayers in medium containing 300 nM of 508 altiratinib and incubated until viable extracellular tachyzoites emerged 8-10 days later. 509 Surviving parasites were passaged once more under continued altiratinib treatment and cloned 510 by limiting dilution. The cloned mutants were each isolated from 6 independent mutagenesis 511 experiments. Thus, each flask contained unique SNV pools.

512

513 **Direct RNA sequencing by nanopore.** The mRNA library preparation followed the SQK-514 RNA002 kit (Oxford Nanopore) recommended protocol, the only modification was the input 515 mRNA quantity increased from 500 to 1000 ng, all other consumables and parameters were 516 standard. Final yields were evaluated using the Qubit HS dsDNA kit (Thermofisher Q32851) 517 with minimum RNA preps reaching at least 150 ng. For all conditions, sequencing was 518 performed on FLO-MIN106 flow cells either using a MinION MK1C or MinION sequencer. 519 All datasets were subsequently basecalled with a Guppy version higher than 5.0.1 with a Qscore 520 cutoff > 7. Long read alignment were performed by Minimap2 as previously described (37). 521 Alignments were converted and sorted using Samtools.

522

523 **Software and Statistical analyses.** Volcano plots, scatter plots, and histograms were generated 524 with Prism 7. Structural representations of *Tg*PRP4K and *Pf*PRP4K/CLK3 were performed 525 using UCSF-Chimera while the schematic representation of altiratinib interaction network was 526 computed using Ligplot.

527

528 List of Supplementary Materials

529 Supplementary Materials and Methods and references

- 530 Fig. S1. Identification of altiratinib by a medium-throughput screening of an FDA-approved
- 531 library.
- 532 Fig. S2. Chemical structures of the 14 compounds selected for their efficacy in inhibiting
- 533 growth of *T. gondii*.
- 534 **Fig. S3.** Representation of T. gondii cytotoxicity after incubation with drugs.
- 535 **Fig. S4.** Origin and interactome of TgPRP4K.
- 536 Fig. S5. Domain architectures of proteins purified together with PRP4K and PRP8.
- 537 **Fig. S6.** Identification and validation of the molecular target TgPRP4K.
- 538 Fig. S7. Comparison of altiratinib resistance in EMS-mutagenized and CRISPR/Cas9-edited
- 539 lines.
- 540 **Fig. S8.** Insect-cell recombinant expression of TgPRP4K.
- 541 **Fig. S9.** Crystal structure specificities of TgPRP4K.
- 542 **Fig. S10.** Altiratinib binding site and interaction network.
- 543 Fig. S11. DRS examples of altiratinib induced splicing defects in *Toxoplasma gondii*.
- 544 **Fig. S12.** DRS examples of altiratinib treatment on *P. falciparum* and *C. parvum*.
- 545 Fig. S13. Biochemistry of recombinant PfPRP4K and chemical structure comparison of
- 546 altiratinib and TCMDC-135051.
- 547 **Table S1.** Table describing the compound library and the selected molecules.
- 548 Table S2. RNA-Seq Analysis of the EMS-Induced Drug-Resistant Lines of T. gondii.
- 549 **Table S3.** Mass spectrometry-based characterization of the interactomes of PRP4K and PRP8.
- 550 **Table S4.** Statistics of crystallographic data.
- 551 **Table S5.** Description of *T. gondii* strains, plasmids and primers.
- 552 Data File 1. Full PDB X-ray structure validation report of crystal structure of Toxoplasma
- 553 TgPRP4K with altiratinib (pdb id: 7Q4A).
- 554

555 **References and Notes**

- 556 1. WHO. World Malaria Report 2021. Who vol. 73 (2021).
- 557 2. J. G. Montoya, O. Liesenfeld, Toxoplasmosis. *Lancet* **363**, 1965–1976 (2004).
- 3. I. R. Dunay, K. Gajurel, R. Dhakal, O. Liesenfeld, J. G. Montoya, Treatment of
 toxoplasmosis: historical perspective, animal models, and current clinical practice. *Clin.*
- 560 *Microbiol. Rev.* **31**, e00057-17 (2018).

- 4. K. Bessoff, A. Sateriale, K. K. Lee, C. D. Huston, Drug repurposing screen reveals
 FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that
 block Cryptosporidium parvum growth. *Antimicrob Agents Chemother.* 57,1804-1814
 (2013).
- 565 5. M. Xu, E. M. Lee, Z. Wen, Y. Cheng, W. K. Huang, X. Qian, J. Tcw, J. Kouznetsova,
 566 S. C. Ogden, C. Hammack, F. Jacob, H. N. Nguyen, M. Itkin, C. Hanna, P. Shinn, C.
 567 Allen, S. G. Michael, A. Simeonov, W. Huang, K. M. Christian, A. Goate, K. J.
 568 Brennand, R. Huang, M. Xia, G. L. Ming, W. Zheng, H. Song, H. Tang, Identification
 569 of small-molecule inhibitors of Zika virus infection and induced neural cell death via a
 570 drug repurposing screen. *Nat Med.* 22, 1101-1107 (2016).
- 571
 6. Y. Kwon, B. D. Smith, Y. Zhou, M. D. Kaufman, A. K. Godwin, Effective inhibition of
 572
 c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced
 573
 by the ovarian tissue microenvironment. *Oncogene* 34, 144–153 (2015).
- B. D. Smith, M. D. Kaufman, C. B. Leary, B. A. Turner, S. C. Wise, Y. M. Ahn, R. J.
 Booth, T. M. Caldwell, C. L. Ensinger, M. M. Hood, W. P. Lu, T. W. Patt, W. C. Patt,
 T. J. Rutkoski, T. Samarakoon, H. Telikepalli, L. Vogeti, S. Vogeti, K. M. Yates, L.
 Chun, L. J. Stewart, M. Clare, D. L. Flynn, Altiratinib Inhibits Tumor Growth, Invasion,
 Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced
 Inhibition of MET, TIE2, and VEGFR2. *Mol Cancer Ther.* 9, 2023-2034 (2015).
- M. M. Alam, A. Sanchez-Azqueta, O. Janha, E. L. Flannery, A. Mahindra, K. Mapesa,
 A. B. Char, D. Sriranganadane, N. M. B. Brancucci, Y. Antonova-Koch, K. Crouch, N.
 V. Simwela, S. B. Millar, J. Akinwale, D. Mitcheson, L. Solyakov, K. Dudek, C. Jones,
 C. Zapatero, C. Doerig, D. C. Nwakanma, M. J. Vázquez, G. Colmenarejo, M. J.
 Lafuente-Monasterio, M. L. Leon, P. H. C. Godoi, J. M. Elkins, A. P. Waters, A. G.
- Jamieson, E. F. Álvaro, L. C. Ranford-Cartwright, M. Marti, E. A. Winzeler, F. J. Gamo,
 A. B. Tobin, Validation of the protein kinase Pf CLK3 as a multistage cross-species
 malarial drug target *Science* 365(6456):eaau1682 (2019).
- 9. A. Mahindra, O, Janha, K. Mapesa, A. Sanchez-Azqueta, M. M. Alam, A. AmambuaNgwa, D. C. Nwakanma, A. B. Tobin, Jamieson AG. Development of Potent PfCLK3
 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. *J Med Chem.*63, 9300-9315 (2020).
- 592 10. M. Schneider, H. H. Hsiao, C. L. Will, R. Giet, H. Urlaub, R. Lührmann, Human PRP4
 593 kinase is required for stable tri-snRNP association during spliceosomal B complex
 594 formation. *Nat Struct Mol Biol.* 17, 216-221 (2010).

- 595 11. M. Lützelberger, N. F. Käufer, The Prp4 Kinase: Its Substrates, Function and
 596 Regulation in Pre-mRNA Splicing. In: Dr. Huang Cai (Ed.), editor. Protein
 597 Phosphorylation in Human Health: InTech. (2012).
- 598 12. D. P. Corkery, A. C. Holly, S. Lahsaee, G. Dellaire, Connecting the speckles: Splicing
 599 kinases and their role in tumorigenesis and treatment response. *Nucleus* 6, 279-88
 600 (2015).
- 13. D. Eckert, N. Andrée, A. Razanau, S. Zock-Emmenthal, M. Lützelberger, S. Plath, H.
 Schmidt, A. Guerra-Moreno, L. Cozzuto, J. Ayté, N. F. Käufer, Prp4 Kinase Grants the
 License to Splice: Control of Weak Splice Sites during Spliceosome Activation. *PLoS Genet.* 12, e1005768 (2016).
- 4. V. Bellini, C. Swale, M. P. Brenier-Pinchart, T. Pezier, S. Georgeault, F. Laurent, M.
 A. Hakimi, A. Bougdour, Target Identification of an Antimalarial Oxaborole Identifies
 AN13762 as an Alternative Chemotype for Targeting CPSF3 in Apicomplexan
 Parasites. *iScience.* 23, 101871 (2020).
- 609 15. E. Talevich, A. Mirza, N. Kannan, Structural and evolutionary divergence of eukaryotic
 610 protein kinases in Apicomplexa. *BMC Evol. Biol.* 11, 321 (2011).
- 611 16. Z. Zhou, X. D. Fu, Regulation of splicing by SR proteins and SR protein-specific
 612 kinases. *Chromosoma* 122, 191–207 (2013).
- 613 17. S. Agarwal, S. Kern, J. Halbert, J. M. Przyborski, S. Baumeister, T. Dandekar, C.
 614 Doerig, G. Pradel, Two nucleus-localized CDK-like kinases with crucial roles for
 615 malaria parasite erythrocytic replication are involved in phosphorylation of splicing
 616 factor. J. Cell. Biochem. 112, 1295–1310 (2011).
- 617 18. S. M. Sidik, D. Huet, S. M. Ganesan, M. H. Huynh, T. Wang, A. S. Nasamu, P. Thiru,
 618 J. P. J. Saeij, V. B. Carruthers, J. C. Niles, S. Lourido, A Genome-wide CRISPR Screen
- 619 in Toxoplasma Identifies Essential Apicomplexan Genes. *Cell.* **166**, 1423-1435 (2016).
- 620 19. V. V. Lee, S. Seizova, P. J. McMillan, E. McHugh, C. J. Tonkin, S. A. Ralph,
 621 Identification and characterisation of splicing regulators in Toxoplasma gondii.
- 622 <u>https://www.biorxiv.org/content/10.1101/2021.06.27.450092v3</u>
- 20. C. A. Bottner, H. Schmidt, S. Vogel, M. Michele, N. F. Käufer, Multiple genetic and
 biochemical interactions of Brr2, Prp8, Prp31, Prp1 and Prp4 kinase suggest a function
 in the control of the activation of spliceosomes in Schizosaccharomyces pombe. *Curr Genet.* 48, 151-61 (2005).
- 627 21. C. Charenton, M. E. Wilkinson, K. Nagai, Mechanism of 5' splice site transfer for
 628 human spliceosome activation. *Science*. 364, 362-367 (2019).

- 629 22. K. Bertram, D. E. Agafonov, O. Dybkov, D. Haselbach, M. N. Leelaram, C. L. Will, H.
 630 Urlaub, B. Kastner, R. Lührmann, H. Stark, Cryo-EM Structure of a Pre-catalytic
 631 Human Spliceosome Primed for Activation. *Cell* **170**, 701–713 (2017).
- 632 23. G. Dellaire, E. M. Makarov, J. J. Cowger, D. Longman, H. G. Sutherland, R. Lührmann,
 633 J. Torchia, W. A. Bickmore, Mammalian PRP4 kinase copurifies and interacts with
 634 components of both the U5 snRNP and the N-CoR deacetylase complexes. *Mol Cell*635 *Biol.* 22, 5141-5156 (2002).
- 636 24. E. A. Greene, C. A. Codomo, N. E. Taylor, J. G. Henikoff, B. J. Till, S. H. Reynolds,
 637 L. C. Enns, C. Burtner, J. E. Johnson, A. R. Odden, L. Comai, S. Henikoff. Spectrum
 638 of chemically induced mutations from a large-scale reverse-genetic screen in
 639 Arabidopsis. *Genetics* 164, 731–740 (2003).
- 640 25. A. D. Tang, C. M. Soulette, M. J. van Baren, K. Hart, E. Hrabeta-Robinson, C. J. Wu,
 641 A. N. Brooks, Full-length transcript characterization of SF3B1 mutation in chronic
 642 lymphocytic leukemia reveals downregulation of retained introns. *Nat Commun.* 11,
 643 1438 (2020).
- 644 26. F. C. Oesterreich, L. Herzel, K. Straube, K. Hujer, J. Howard, K. M. Neugebauer,
 645 Splicing of nascent RNA coincides with intron exit from RNA polymerase II. *Cell*, 165,
 646 372–381 (2016).
- 647 27. L. Herzel, K. Straube, K. M. Neugebauer, Long-read sequencing of nascent RNA
 648 reveals coupling among RNA processing events. *Genome Res.*, 28, 1008–1019 (2018).
- 28. J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K.
 Tunyasuvunakool, R. Bates, A. Žídek, A. Potapenko, A. Bridgland, C. Meyer, S. A. A.
 Kohl, A. J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T.
 Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska,
 T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A. W. Senior, K. Kavukcuoglu,
 P. Kohli, D. Hassabis, Highly accurate protein structure prediction with AlphaFold. *Nature*. 596, 583-589 (2021).
- 656 29. M. Mirdita, S. Ovchinnikov, M. Steinegger, ColabFold Making protein folding
 657 accessible to all. <u>https://www.biorxiv.org/content/10.1101/2021.08.15.456425v1</u>
 658 (2021).
- 30. S. C. Artim, J. M. Mendrola, M. A. Lemmon, Assessing the range of kinase
 autoinhibition mechanisms in the insulin receptor family. *Biochem J.* 448, 213-220
 (2012).

- 31. J. M. Mendrola, F. Shi, J. H. Park, M. A. Lemmon, Receptor tyrosine kinases with
 intracellular pseudokinase domains. *Biochem Soc Trans.* 41, 1029-1036 (2013).
- 32. C. H. Yun, T. J. Boggon, Y. Li, M. S. Woo, H. Greulich, M. Meyerson, M. J. Eck,
 Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism
 of activation and insights into differential inhibitor sensitivity. *Cancer Cell.* 11, 217-27
 (2007).
- 33. T. Nakaoku, T. Kohno, M. Araki, S. Niho, R. Chauhan, P. P. Knowles, K. Tsuchihara,
 S. Matsumoto, Y. Shimada, S. Mimaki, G. Ishii, H. Ichikawa, S. Nagatoishi, K.
 Tsumoto, Y. Okuno, K. Yoh, N. Q. McDonald, K. A. Goto, A secondary RET mutation
 in the activation loop conferring resistance to vandetanib. *Nat Commun.* 9, 625 (2018).
- 34. M. Hoemberger, W. Pitsawong, D. Kern, Cumulative mechanism of several major
 imatinib-resistant mutations in Abl kinase. *Proc Natl Acad Sci USA*. 117, 19221-19227
 (2020).
- 675 35. W. Trager, J. B. Jensen, Human malaria parasites in continuous culture. *Science* 193,
 676 673–675 (1976).
- 677 36. D. C. Farhat, C. Swale, C. Dard, D. Cannella, P. Ortet, M. Barakat, F. Sindikubwabo,
 678 L. Belmudes, P. J. De Bock, Y. Couté, A. Bougdour, M. A. Hakimi, A MORC-driven
 679 transcriptional switch controls Toxoplasma developmental trajectories and sexual
 680 commitment. *Nat Microbiol.* 5, 570-583 (2020).
- 37. D. C. Farhat, M. W. Bowler, G. Communie, D. Pontier, L. Belmudes, C. Mas, C. Corrao,
 Y. Couté, A. Bougdour, T. Lagrange, M. A. Hakimi, C. Swale, A plant-like mechanism
 coupling m6A reading to polyadenylation safeguards transcriptome integrity and
 developmental gene partitioning in Toxoplasma. *Elife*. 10, e68312 (2021).
- 685

686 Acknowledgments. This work was supported by the Laboratoire d'Excellence (LabEx) 687 ParaFrap [ANR-11-LABX-0024], the Agence Nationale pour la Recherche [Project HostQuest, 688 ANR-18-CE15-0023, Project ApiNewDrug, ANR-21-CE35-0010-01, Project EpiKillMal, 689 ANR-20-CE18-0006], the European Research Council [ERC Consolidator Grant N°614880 690 Hosting TOXO to M.A.H], and Fondation pour la Recherche Médicale [FRM Equipe # 691 EQU202103012571] and Roux-Cantarini Fellowship attributed to FN. The proteomic 692 experiments were partially supported by Agence Nationale de la Recherche under projects 693 ProFI (Proteomics French Infrastructure, ANR-10-INBS-08) and GRAL, a program from the 694 Chemistry Biology Health (CBH) Graduate School of University Grenoble Alpes (ANR-17-

695 EURE-0003). The HTX Lab (EMBL Grenoble) are thanked for support in screening for crystal 696 conditions and automatic mounting of crystals. Author Contributions. M.-A.H. led the 697 research and coordinated the collaboration. M.-A.H. A.B. and C.S. designed the project. Y.C. 698 and L.B. performed the mass spectrometric analyzes. F.L. designed and performed experiments 699 on Eimeria and Cryptosporidium. A.S. and F.N. designed and performed experiments on 700 Plasmodium falciparum. A.B. computed and analyzed the RNA-seq data. V.B. performed the 701 drug screening. V.B. and D. C. performed the in vitro studies with T. gondii. M.-P.B.-P. and 702 V.B. designed and performed the in vivo experiments with T. gondii. C.S. and MWB performed 703 structural studies. C.S. and C.M. performed the MST and SEC-MALLS. C.S. performed 704 nanopore DRS and analyzed them. V.B. and C.S. designed and performed biochemical studies. 705 M.-A.H., A.B., and C.S. interpreted the experimental work and wrote the paper with editorial 706 support from V.B. and fruitful comments from all other authors. Data availability. All data 707 associated with this study are in the paper or the Supplementary Materials. All unique and stable 708 reagents generated in this study are available by contacting M.A.H. and completion of a 709 materials transfer agreement. The Nanopore RNAseq data have been deposited in NCBI's SRA 710 data PRJNA774463. The Illumina RNA-seq dataset generated during this study is available at 711 NCBI GEO: GSE193614. The coordinates and structure factors for the TgPRP4k/altiratinib 712 structure have been deposited in the PDB with the accession number 7Q4A. The mass 713 spectrometry proteomics data were deposited with the ProteomeXchange Consortium via the 714 PRIDE partner repository with the record identifier : pxd029455. Declaration of Interests. 715 The authors declare no competing interests.

716

717 Figures caption.

718

719 Fig. 1. Efficacy of altiratinib against the parasite Toxoplasma gondii. (A) Graphical representation of data from the medium-throughput screen. A cutoff was set at 70% of parasite 720 721 inhibition. Red dots, hits. The workflow used for the screening is shown in Fig. S1A. (B) The 722 half-maximal effective concentration (EC₅₀) values of the 14 molecules validated at 1µM. Data 723 are presented as mean \pm standard deviation (SD) of n=3 technical replicates. Error bars 724 correspond to 95% confidence intervals. (C) Chemical structure of altiratinib. (D) EC₅₀ values 725 for pyrimethamine and altiratinib. The confluent HFF monolayer was infected with tachyzoites 726 of the *T. gondii* RH NanoLucEmGFP strain (Table S5). The EC₅₀ values of each biological 727 replicate were determined by non-linear regression analysis. EC₅₀ data are presented as mean

728 G SD from 3 independent biological replicates, each with 3 technical replicates. (E) Compound 729 efficiency presented by IFA. Confluent HFFs were infected with T. gondii 730 RH NanoLucEmGFP and incubated with 1µM of pyrimethamine, 300 nM of altiratinib or 731 0.1% of the vehicle (DMSO) for 24h. Fixed cells were stained with anti-inner membrane 732 complex protein (GAP45) antibody (magenta). In green the cytosolic GFP. Scale bar 733 corresponds to 5µm. (F) Dose-response curves of HFFs, ARPE-19, MCF7, MDA231 and U937 734 cell lines in the presence of altiratinib. Human cells were plated out and incubated with 735 increasing concentrations of the drug. After 72h, cell viability was determined using the 736 "CellTiter-Blue Assay" kit (Promega) and cell cytotoxicity concentration (CC50) was 737 calculated. The graph is representative of two different experiments performed in triplicate. The 738 shaded error envelopes indicate 95% confidence intervals. On the right, CC50 values show the 739 mean of two experiments. Selectivity index (SI) is based on the average of human CC50 divided 740 by the average of *T. gondii* EC50. (G) Effect concentration curve of *Eimeria tenella* in presence 741 of altiratinib. (H) Altiratinib inhibition of *Neospora caninum* proliferation shown by plaque 742 assay. After 7 days of infection and drugs incubation, the size of at least 50 plaques were 743 measured. n.d., not detected. (I) Dose-response curves of altiratinib and dihydroartemisinin 744 (DHA) in *P. falciparum* asexual blood-stage. Graph is representing the mean and SD values 745 obtained in three independent experiments run in triplicate.

746

747 Fig. 2. Deconvolution and validation of the TgPRP4K molecular target. (A) Circos plot 748 summarizing the single nucleotide variants (SNVs) detected by transcriptomic analysis of T. 749 gondii altiratinib-resistant lines, grouped by chromosome (numbered in Roman numerals with 750 size intervals indicated on the outside). Each dot in the six innermost gray tracks corresponds 751 to a scatter plot of the mutations identified in the six drug-resistant strains, with each ring 752 representing one of the six drug-resistant lines (A through F). Each bar in the outermost track 753 represents the positions of selected archetypal essential genes. See Table S2 for transcriptomic 754 analysis. (B) Schematic representation of the TgPRP4K protein structure. The kinase domain is 755 predicted in the C-terminal portion of the protein. Phosphorylated and acetylated residues are 756 shown as blue and red dots, respectively. The orange dots correspond to the three discovered 757 SNVs located in the kinase domain. (C) The nuclear location of TgPRP4K (red) in human 758 primary fibroblasts (HFFs) infected with parasites expressing an HA-Flag-tagged copy of 759 TgPRP4K. Cells were co-stained with Hoechst DNA-specific dye (blue) and the anti-Inner 760 Membrane Complex (IMC) (green) antibody. Scale bar, 5 µm. (**D**) Graphs representing the 761 essentiality of TgPRP4K protein assessed by plaque assay. RH Tir1-Ty and TgPRP4K KD

762 parasites were either untreated or treated with IAA for 7 days and the size of 42 plaques were 763 measured upon detection. n.d., not detected. (E) Fluorescence microscopy showing intracellular 764 growth of WT and the TgPRP4K edited parasites (F647S, L686F, L715F). HFF cells were 765 infected with tachyzoites of the indicated T. gondii strains expressing the NLuc-P2A-EmGFP 766 reporter gene and incubated with 300 nM of altiratinib or 0.1% DMSO as control. Cells were 767 fixed 24 h post-infection and then stained with antibodies against the *T. gondii* inner membrane 768 complex protein GAP45 (magenta). The cytosolic GFP is shown in green. Scale bars represent 769 5 μm. (F) EC₅₀ values for pyrimethamine (Pyr) and altiratinib were determined for WT and the 770 engineered TgPRP4K mutant strains (F647S, L686F, L715F). The EC50 values on the upper 771 part of the graphs represent the mean \pm SD of three biological replicates. On the top of each 772 panel, lines shown the fold change in EC_{50} relative to that of the WT parasites. Dose-response 773 curves are shown in Fig. S6C. (G) Effects of TgPRP4K mutations on T. gondii lytic cycle as 774 determined by plaque assay. Plaque sizes (n = 50 per condition) were measured for WT and the 775 engineered TgPRP4K mutant strains (F647S, L686F, L715F) after 7 days of growth in the 776 absence or presence of 300 nM of altiratinib. n.d., not detected. Significance was assessed by 777 Mann-Whitney or Kruskal-Wallis tests (One-way ANOVA).

778

779 Fig. 3. Structure of the complex TgPRP4K-altiratinib and mechanism of action. (A) 780 Thermal stability profile of WT (upper panel) and L715F (bottom panel) recombinant proteins. 781 Each protein was incubated for 3 minutes at different temperatures (from 30° to 69° C) in 782 presence or absence of Altiratinib (100 µM) to quantify the melting temperatures using non-783 linear regression analysis of normalized data and assuming a sigmoidal dose response. (B) 784 Protein-Ligand interaction. WT and L715F recombinant proteins labelled to His-fluorescent 785 dye (100 nM), were incubated with altiratinib from 0.15 nM to 5000 nM. Changes in 786 thermophoresis were plotted as mean changes in Fnorm values against ligand concentration, 787 yielding a Kd of 64 ± 20 nM for WT (upper panel) and 26 ± 2 nM for L715F (bottom panel). 788 Curve 95% confidence intervals are displayed; n = 3. (C) Full structure of TgPRP4K (L715F) 789 bound to altiratinib (pdb id: 7Q4A). PRP4K is represented in a cartoon fashion with a 790 transparent surface background with alpha helices colored in orange and beta strands colored 791 in yellow. The activation loop is highlighted in blue, the DFG backbone is shown in pink, the 792 phosphor-serine 729 side chain and altiratinib are shown in a stick representation and colored 793 in grey and cyan respectively. (**D**) Altiratinib binding within TgPRP4K. Zoomed in focus on 794 altiratinib and the key interacting side chains of TgPRP4K shown as grey sticks. Cartoon colors are the same as used in panel a. (E) Sequence alignment of altiratinib TgPRP4K binding regions compared against *Plasmodium falciparum* (*Pf*), *Chromera Velia* (cc), *Schizosaccharomyces pombe* (*Sp*), *Arabidopsis thaliana* (*At*) and *Homo sapiens* (*Hs*) PRP4K/CLK3 orthologs. Key regions are highlighted by pink rectangles, altiratinib interacting amino acids from TgPRP4Kare shown by cyan circles while divergent residues in the human ortholog are shown by red triangles. Mutations found in the mutagenesis experiment are highlighted by a green star. The alignment was generated with CLC sequence viewer 7.


802


803 Fig. 4. Hinge region selectivity towards altiratinib. (A) Hinge region species selectivity 804 towards altiratinib. Cartoon diagram of structurally superposed TgPRP4K (tan) and human 805 PRPF4B (sky blue) with altiratinib in cyan. Hinge region residues are detailed by including 806 stick representations of their side chains. (B) Sanger chromatogram validating the $T_g PRP4K$ 807 gene editing for W649P mutation. On the top, nucleotide positions relative to the ATG start 808 codon on genomic DNA are indicated. (C) IFA showing the W649P resistance to altiratinib. 809 Confluent HFFs were infected with engineered parasites and incubated with pyrimethamine (1 810 µM) or altiratinib (300 nM) for 24h. Fixed cells were stained using anti-GAP45 antibody 811 (magenta) while the cytosolic GFP is showed in green. Scale bar represents 5 µm. (**D**) Graph 812 representing the EC₅₀ of W649P for pyrimethamine and altiratinib. Values showed in the upper 813 part on the graph are the mean \pm SD of three independent experiment. On the top of the panel, 814 the line shows the fold change in altiratinib EC_{50} relative to pyrimethamine. (E) Plaque assay 815 representing the lytic cycle of RH WT and W649P parasites in presence or absence of 300 nM 816 of altiratinib. After 7days of drugs incubation, infected cells were fixed and stained to visualize 817 the presence of lysis plaques (on the left). The area of 50 plaques was measured and represented 818 in the right panel. (F) Thermal stability profile of W649P recombinant protein in presence or 819 absence of Altiratinib (100 µM). (G) Protein-ligand interaction profile of W649P protein in 820 presence of Altiratinib as measured by thermophoresis with the same assay used in Fig. 3b. 821 Changes in thermophoresis of the mean of three replicates were plotted. Curve 95% confidence 822 intervals are displayed as dotted lines. NA, not available. (H) Table showing the melting 823 temperature (Tm) of WT, L715F and W649P recombinant proteins during their incubation with 824 DMSO or Altiratinib (100 μ M) at different temperatures. Low interaction between W649P and 825 the compound was detected as showed by the ΔTm values. (I) Kinase activity inhibition in 826 vitro. KinaseGlo® remaining ATP levels were measured and normalized for every condition.


The normalized endpoint activity is plotted against altiratinib concentrations. 4-parameter
inhibition curves were used to determine an apparent IC50 for WT, L715F and W649P mutant.


- 830 Fig. 5. Nanopore DRS analysis of altiratinib-induced splicing defects in T. gondii. (A) 831 General transcriptomic effects of altiratinib treatment. k-means clustering of 2400 transcripts 832 treated with EdgeR: log2(CPM+4). The color key ranges from -3 to 3 (green to red), 3 clusters 833 were defined. In each, TgPRP4K WT/L715F/W649P duplicate sequencing experiments are 834 shown in the presence (300 nM) or absence of altiratinib. (B) M-pileup representation of the 835 aligned nanopore reads at the TGME49 214940 loci. WT/L715F/W649P sequencing 836 experiments are shown as grayscale histograms in the presence (300 nM) or absence of 837 altiratinib. (C and D), FLAIR analysis of TGME49 211420 (C) and TGME49 214940 (D) loci. 838 Standard annotation and FLAIR collapsed isoforms (FCI) are shown schematically under a 839 sample view of 15 reads per condition (same conditions as in **B**). Sense and antisense reads are 840 colored red and blue, respectively. Below the FCI representation is an isoform quantification 841 histogram showing duplicate measurements in each WT/L715F/W649P condition and in the 842 presence (300 nM) or absence of altiratinib. The color code is the same as for the above FCI, 843 grey histograms represent minor isoforms which not shown schematically. (E) Overall 844 quantification of intron retention. Scatter plot of intron retention ratios (per averaged duplicate 845 transcript) are shown for T. gondii and H. sapiens. WT/L715F/W649P strains that were 846 untreated (in green) or treated (300 nM, in cyan) are shown, the black histogram shows the 847 median, the whiskers show the interquartile range. Significance between the WT untreated and 848 treated conditions was calculated using a non-parametric Friedman test.
- 849


850 Fig. 6. Cross-species selectivity of altiratinib analysed by nanopore DRS. (A) Splicing 851 defects induced by altiratinib in P. falciparum. M-pileup representation of aligned nanopore 852 reads at the PF3D7 0918100 and PF3D7 1118700 loci. Untreated (UT) or altiratinib-treated 853 (2.5 µM) sequencing experiments are shown as grayscale histograms. Shown below are IGB 854 samples from 10 individual aligned reads using sense (purple) and antisense (blue) coloring 855 under UT and treated conditions. (B) Overall quantification of intron retention in *P. falciparum*. 856 Scatter plots of intron retention ratios (per averaged duplicate transcript) are shown for 857 untreated (in green) or altiratinib treated (in cyan) conditions, the black histogram shows the 858 median, the whiskers show the interquartile range. Significance between the WT untreated and 859 treated conditions was calculated using a nonparametric Mann-Whitney t-test. (C) Splicing 860 consistency is maintained in C. parvum. M-pileup and IGB sampling of aligned reads from 861 untreated (UT) or altiratinib treated (0.5 µM) C. parvum at the highly transcribed and spliced 862 cdg6 4620 loci. (**D**) Overall quantification of intron retention in C. parvum. The same display rules as in **B**. were applied. (**E**) Thermal shift assay of TgPRP4K and PfCLK3 in the presence 863 864 of altiratinib (100 µM) or TCDM-135051 (100 µM). A simplicate assay is shown, but the measurement was replicated. (F) Hinge region species selectivity towards TCMD-135051. 865 866 Cartoon diagram of the structurally superposed TgPRP4K from this work (in tan) and the 867 alphaflod2 predicted PfCLK3 (dodger blue) with TCDM-135051 modelling in orange. The 868 residues of the hinge region are also detailed by showing their side chains as stick 869 representations.














Figure 4

